Mount Sinai Health System Launches i3 Prism, a Technology Commercialization Fund focused on Female and BIPOC Inventors
i3 Prism aims to bring new health care solutions to patients and society by advancing technologies from women and BIPOC inventors closer to the marketplace.
Mount Sinai Innovation Partners (MSIP), the commercialization arm of the Mount Sinai Health System in New York, New York, has launched i3 Prism, a technology commercialization fund focused on women and Black, Indigenous and people of color (BIPOC) health care innovators.
This unique opportunity empowers diverse innovators, including Mount Sinai’s faculty, staff, and students, to help advance technologies and develop commercialization plans. Participating innovators can receive up to $33,000 in funding, based on their work’s milestone achievements, in an effort to bring innovations to life and improve health and well-being for all people.
MSIP and its collaborators aspire to increase access to funding for Mount Sinai inventors, regardless of field, and the fund is available to all teams across the entire Health System. i3 Prism is the newest addition to Mount Sinai’s i3 (innovation, inflection and impact) family of funds, supporting innovation and advancing Mount Sinai technologies.
“i3 Prism will enable women and BIPOC innovators to take the next step in advancing breakthrough health care technologies to benefit patients,” said Erik Lium, PhD, President of MSIP and Chief Commercial Innovation Officer of Mount Sinai. “This fund will directly support i3 Prism awardees in bringing their solutions to the next level.”
The fund was launched by MSIP, in collaboration with the Diversity and Innovation Hub, led by Gary C. Butts, MD, Executive Vice President and Chief Diversity and Inclusion Officer for the Mount Sinai Health System and Dean for Diversity Programs, Policy, and Community Affairs, Icahn School of Medicine at Mount Sinai; Mount Sinai BioDesign, directed by Joshua Bederson, MD, Leonard I. Malis, MD/Corinne and Joseph Graber Professor and System Chair of Neurosurgery, and Benjamin Rapoport, MD, PhD, Assistant Professor of Neurosurgery; the Graduate School of Biomedical Sciences, led by its Dean, Marta Filizola, PhD, Sharon and Frederick Klingenstein/Nathan Kase, MD Professor; the Windreich Department of Artificial Intelligence and Human Health, chaired by Thomas J. Fuchs, DrSc, Barbara T. Murphy, MD Professor of Artificial Intelligence and Human Health; the BioMedical Engineering and Imaging Institute at Icahn Mount Sinai, directed by Zahi Fayad, PhD, Lucy G. Moses Professor in Medical Imaging and Bioengineering; and the Mount Sinai ConduITS – Institutes for Translational Sciences, directed by Rosalind Wright, MD, MPH, Principal Investigator and Dean for Translational Biomedical Sciences.
About Mount Sinai Innovation Partners (MSIP)
Mount Sinai Innovation Partners (MSIP) is responsible for driving the real-world application and commercialization of Mount Sinai discoveries and inventions, and the development of research partnerships with industry. Our aim is to translate discoveries and inventions into healthcare products and services that benefit patients and society. MSIP is accountable for the full spectrum of commercialization activities required to bring Mount Sinai inventions to life. These activities include evaluating, patenting, marketing and licensing new technologies building research, collaborations and partnerships with commercial and nonprofit entities, material transfer and confidentiality, coaching innovators to advance commercially relevant translational discoveries, and actively fostering an ecosystem of entrepreneurship within the Mount Sinai research and health system communities. For more information, please visit ip.mountsinai.org/ or find MSIP on LinkedIn, Twitter, Facebook, Medium, and YouTube.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report's Best Hospitals, receiving high "Honor Roll" status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children's Hospital among the country’s best in several pediatric specialties.